Answer: E
ANDROMEDA was a survival study in patients with systolic left ventricular dysfunction. The trial was prematurely discontinued because of increased mortailty attributable to worsening of heart failure in the dronedarone group. 6 months later, mortality rates were similar (13·5% for dronedarone vs 12·3% for placebo; hazard ratio [HR] 1·13, 95% CI 0·73—1·74, p=0·60), but dronedarone is nevertheless contraindicated in class III and IV heart failure.
Reference
Dobromir Dobrev, Stanley Nattel. New antiarrhythmic drugs for treatment of atrial fibrillation The Lancet, Early Online Publication, 23 March 2010 (Link)